Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2018

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 9 X posts from 3 X users, with an upper bound of 22,122 followers.

RT @sitcancer: #JITC Research: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV #melanoma…

#JITC Research: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV #melanoma: a case series https://t.co/96PCXmCMOC https://t.co/yv5Dzs5C6G

RT @sitcancer: #JITC Research: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV #melanoma…

#JITC Research: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV #melanoma: a case series https://t.co/LghwDAGt60 https://t.co/sToR3buIJG

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.